What we do
Stemina is the world leader in building human cellular models for toxicity screening of drug candidates, chemical compounds, cosmetic and tobacco ingredients. Our developmental toxicity assays are the only human system for assessing the risk that a compound will cause birth defects if a woman is exposed during pregnancy.
MORE ABOUT US

What we do

Toxicology

Stemina's toxicology assays are the only human in vitro assays for developmental toxicity screening.

LEARN MORE

Technologies

Stemina's metabolomics platform and expertise in cellular models can be used for custom projects.

LEARN MORE

Our Team

Stemina has assembled a world class team of scientists and experts. Meet our team.

LEARN MORE

Latest news

Aug 25

Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, PhD, Former Head of Roche Molecular Diagnostics

Aug 25, 2017
Dr. Driesmann, a leader in the diagnostics industry, will guide Stemina’s commercialization strategy. Read the full press release.

Read more
Aug 23

EU-ToxRisk Case Study: Developmental Toxicity Potency of Valproate Analogues in Human Pluripotent Stem Cell-Based Assay

Aug 23, 2017
Presented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer. The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade;

Read more
Aug 16

Utilizing devTOXqP in a Combined Testing Approach for Identifying Developmental Toxicity Liability of Chemicals [Webinar Slides]

Aug 16, 2017
Why develop devTOX? Reduce prevalence of birth defects and decrease animal testing. Our approach represents a unique opportunity to screen compound safety using a human endpoint. devTOX quickPredict is a predictive, targeted biomarker assay. (devTOX Discovery, on the other hand, is a predictive, untargeted metabolomics assay.) Jessica Palmer presented this webinar in October 2016. If

Read more